Mai Chun Wai

Dr Mai Chun Wai

Mai Chun Wai

Designation  Lecturer

PhD in Medical and Health Sciences (By Research), BPharm (Hons) (IMU)

School / Centre

School of Pharmacy

Department

Pharmaceutical Chemistry

Division

Pharmacy

Education & Training

(What) (Where) (Year)
Complementary Medicine Education (CMEd) Certification Blackmores Institutes, Australia 2018
SEA-EU-NET II Fellowship European Union 7th Framework Programme 2016
Visiting Researcher National Research Council, Italy 2016
YPASM Research Fellow British Antarctic Survey, Cambridge, United Kingdom 2015-2016
Doctor of Philosophy in Medical and Health Sciences International Medical University 2014
Research Fellow/Visiting Researcher University of Strathclyde, Glasgow, United Kingdom 2013
Good Clinical Practice Certificate Ministry of Health, Malaysia 2012
Bachelor of Pharmacy (Hons) International Medical University 2009
     
     

Skills & Expertise

(1) Targeting Cancer Immune Evasion
Our research work concerns the fundamental mechanisms of cancer progress and to identify potential treatment strategy. Our team primary focuses on understanding the cancer carcinogenesis and the pathophysiology of cancer, with the ultimate aim to improve early detection and diagnosis of cancer. We focus in understanding cancer immunology, an interdisciplinary branch of cancer that focuses on the role of immune system in the progression and development of cancer. Cancer microenvironment is a complex cancer defense mechanism which keeps the cancer cells evade from the attack of host immune cells. Several biomarkers and checkpoint synapse markers have been postulated to shield the cancer cells from immune cells and thus confers the immune evasion in cancers. However, the exact cancer biomarkers that responsible on the cancer immune evasion has yet been identified. It is evidence that current clinical trial agents, including the immunotherapies, have yet to achieve complete cancer regression. We are currently using both in silico data mining and in vitro molecular biology studies to understand the cancer immune evasion mechanism. Building on my PhD study on Toll-like Receptor-4 in cancers, our research team postulates the innate and adaptive immune system are responsible of the cancer immune evasion. Through collaborations with national and international academic as well as industry partners we seek to understand the fundamental mechanism of immune evasion in cancer. Ultimately, our team is aiming to improve the diagnosis and treatment of gastrointestinal cancer, especially pancreatic cancer.

(2) Collaborative Drug Discovery Programme
Future cancer drug discovery relies on finding solutions for complex unmet medical needs. Through a better understanding of the cancer pathophysiology, we are at the right position to propose a treatment strategy. Our research team put together the Collaborative Drug Discovery (CDD) Program to establish a network with academic and biotechnology industries to provide access to disease-relevant phenotypic and target- based assays. Investigators can take advantage of this resource which will open new venues to test novel therapeutic hypotheses and deepen our understanding of complex biological systems. Through this initiative and others, our steadfast goal remains focused on the discovery of novel therapeutics that improve patients’ lives, our ultimate measure of success. We have identified several potential compounds with selective anticancer properties, yet minimum cytotoxicity to isogenic cells. Further studies are on-going to delineate its anticancer properties.

KPT/JPT(R/010/3/0186)09/2023
KPT/JPT(R2/721/6/0033)09/2026
KPT/JPT(R2/721/6/0025)03/2023
KPT/JPT(R2/724/6/0010)01/2023
KPT/JPT(R2/727/6/0050)09/2026
KPT/JPT(R2/442/6/0003)01/2023
KPT/JPT(R2/442/6/0003)01/2023
KPT/JPT(R2/726/6/0021)09/2022
KPT/JPT(R/726/6/0011)06/2022
KPT/JPT(R2/421/6/0011)09/2022
KPT/JPT(R2/545/6/0014)09/2022

KPT/JPT(R2/311/6/0013)09/2022
KPT/JPT(R/726/6/0054)08/2026
KPT/JPT(R2/721/6/0059)01/2027
KPT/JPT(R/723/6/0125)04/2020
KPT/JPT(R2/723/6/0101)01/2024
KPT/JPT(R2/721/6/0025)03/2023
KPT/JPT(R/720/7/0077)09/2020
KPT/JPT(R-CDL/442/7/0001)01/2022
KPT/JPT(R/545/7/0078)07/2022
KPT/JPT(R2/720/7/0049)06/2026

KPT/JPT(R/721/8/0043)01/2020
KPT/JPT(N/727/7/0051)03/2024
KPM/JPT(N/145/7/0064)09/2020
KPM/JPT(N/145/7/0066)09/2020
KPM/JPT(N/145/7/0070)09/2020
KPT/JPT(N/724/7/0019)06/2021
KPT/JPT(N/726/7/0030)02/2023
KPT/JPT(N/721/7/0071)03/2022
KPT/JPT(N/345/7/1082)9/2023
KPT/JPT(N/345/7/1085)10/2023
KPT/JPT(N/345/7/1090)12/2023


Cert No: KLR 0500119